TetraPhase's Series C
This article was originally published in Start Up
Executive Summary
Anti-infective developer TetraPhase Pharmaceuticals announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. The financing is one of the richest of the year, just below the April $56 million Series C pulled in by Achaogen, which is also developing antibiotics for drug resistant diseases. And it far exceeds the average Series C financing of $19.77 million raised between January and May of this year.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.
Start-Up Quarterly Statistics, Q2 2010
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.